13F Holdings
中文EN

NSRX Nasus Pharma Ltd Annual reports only

Pharmaceutical Preparations · NYSE · SEC CIK 2029039 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-282.2%
TTM EPS YoY-227.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-0.4%
Net margin-0.5%
FCF margin-0.4%
EBITDA margin—

Returns

ROE—
ROA-204.7%
ROIC (approx.)—
Asset turnover431.74x

Leverage & solvency

Liabilities / assets44.7%
Debt / equity0.00x
Current ratio2.24x
Interest coverage62.87x

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-32.8%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue$1.24B——
R&D expense$2.24M$335,000$567,000
SG&A expense$2.67M$743,000$580,000
Operating income-$4.90M-$1.08M-$1.15M
Interest expense-$78,000$29,000$49,000
Net income-$5.86M-$1.53M-$1.05M
EPS (basic)-0.72-0.22-0.15
EPS (diluted)-0.72-0.22-0.20
Weighted avg. shares (diluted)8.01M7.03M7.06M
Balance sheet
Cash & equivalents$1.24M$284,000$193,000
Current assets$4.86M$457,000—
PP&E, net$14,000——
Total assets$5.00M$717,000—
Current liabilities$2.16M$3.93M—
Total liabilities$2.24M$3.93M—
Shareholders' equity$2.77M-$3.21M-$3.80M
Shares outstanding9.02M7.36M—
Cash flow statement
Operating cash flow-$4.92M-$665,000-$1.03M
Capital expenditure$14,000——
Free cash flow-$4.93M——
Investing cash flow-$3.01M——
Financing cash flow$8.92M$770,000$1.05M
Stock-based compensation$447,000$10,000$39,000

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.